Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- **n/a**
  - The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
  - A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
  - The statistical test(s) used AND whether they are one- or two-sided
  - Only common tests should be described solely by name; describe more complex techniques in the Methods section.
  - A description of all covariates tested
  - A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
  - A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
  - For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted. Give P values as exact values whenever suitable.
  - For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
  - For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
  - Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

- **Data collection** Flow cytometry data were collected using BD LSRFortessa and analyzed with FlowJo version 7.6 (Tree Star, US).
- **Data analysis** Statistical differences between treatment and control groups were evaluated by SigmaStat v3.5 (Systat Software, London, UK). Sample size was determined by G*Power 3.1.7.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The source data under lying Figs 1a, 1e-h, 2a-g, 3b, 3d-e, 4a-b, 4d-f, 5a-j, 6a-g, 7a-d and Supplementary Figs 1a-b, 2d-f, 3a, 3d-e, 4a-b, 5b-e, 7a-b, 7d-e, 8a, 8c-d, 9a and 9c are provided as a Source Data file. All the other data supporting the findings of this study are available within the article and its supplementary information files and from the corresponding author upon reasonable request.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Sample size | The sample sizes were determined based on pilot studies and previous publications (Rao, et al. Hepatology (2016) 64(2):456-472; Lu et al. Journal of Hepatology (2017) 67:739–748). Most experiments were performed multiple times. If results were reproducible, the conclusions were consider valid. |
| Data exclusions | no data were excluded from the study. |
| Replication | all attempts at replication were successful. How many times each experiment was performed and which statistical analysis used is indicated in the figure legends. |
| Randomization | all samples were randomly allocated into experimental groups. |
| Blinding | the investigators were not blinded to the group allocation during data collection and / or data analysis because all samples were analyzed in the same way. |

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems | Methods |
| --- | --- |
| n/a | n/a |
| ✗ | Χ Antibodies |
| ✗ | ✗ Eukaryotic cell lines |
| Χ | ✗ Palaeontology |
| ✗ | ✗ Animals and other organisms |
| ✗ | Χ Human research participants |
| Χ | ❏ Clinical data |
| Χ | Χ ChIP-seq |
| ❏ | ❏ Flow cytometry |
| ❏ | Χ MRI-based neuroimaging |

Antibodies

Antibodies are listed below as: target label (company, catalog number, dilution)

FITC- anti-mouse IgG2b Isotype (Biolegend,402207):1:500
PE- anti-mouse IgG2b Isotype (Biolegend,402203):1:500
PE – cy7anti-mouse IgG2b Isotype (eBioscience,25-4031-81):1:500
APC- anti-mouse IgG2b Isotype (Biolegend,402205):1:500
FITC-anti-mouse MHCII (eBioscience,11-5958-80):1:250
FITC-anti-mouse MHCII (Biolegend,116405):1:250
FITC-anti-mouse CD80 (abcam,ab24860):1:250
PE- anti-mouse CD83 (Biolegend,121507):1:250
APC-anti-mouse CD86 (eBioscience,17-0862-82):1:250
PE-cy5.5 anti-mouse CD11c (eBioscience,35-0114-82):1:250
FITC-anti-mouse CD45(Biolegend,103107):1:500
percp-cy5.5-anti-mouse CD45(Biolegend,103131):1:500
FITC-anti-mouse CD3(eBioscience,11-0031-82):1:500
PE-anti-mouse CD3(eBioscience,12-0031-82):1:500
PE-cy7-anti-mouse CD3(eBioscience,25-0032-80):1:500
PE-anti-mouse CD4 (eBioscience,12-0041-83):1:500
APC-anti-mouse CD8a (Biolegend,100712):1:500
PE-anti-mouse CD11c (Biolegend,117308):1:250
BV421-anti-mouse CD11b(Biolegend,101236):1:500
FITC-anti-mouse B220/CD45R(eBioscience,11-0452-81):1:500
PE-cy7-anti-mouse CD19(Biolegend,115519):1:500
APC-anti-mouse-NK1.1(eBioscience,17-5941-81):1:500
PE-cy7-anti-mouse CD25(eBioscience,25-0251-81):1:500
PE-anti-mouse CD62L(eBioscience,12-0621-81):1:500
FITC-anti-mouse CD44(eBioscience,11-0441-81):1:500
PE-cy7-anti-mouse CD127(eBioscience,25-1273-80):1:500
### Eukaryotic cell lines

**Policy information about cell lines**

| Cell line source(s) | Murine dendritic cell line DC2.4 was provided by Dr De Yang, Center for Cancer Research, NIH, US. Murine HCC cell line Hepa1-6 was purchased from Boster Biological Technology Ltd (Wuhan, China). Murine pancreatic cancer cell line (Panc02, H-2b), Lewis lung cancer cell line (LLC1, H-2b), breast cancer cell line (4T1, H-2d), cervical cancer cell (Hela) and lymphoma cell (EL4) lines were kept in house and originally purchased from ATCC biobank. Human HCC cell lines including HepG2, Hep3B, Panc1 and MCF7 were purchased from ATCC biobank; MHCC -97H was purchased from Shanghai Institute for Biological Sciences, Chinese Academy of Sciences and LM3 was purchased from BeNa Culture Collection, Beijing, China. |
| Authentication | none of the cell lines used were authenticated |
| Mycoplasma contamination | all cell lines were tested negative for mycoplasma contamination |
| Commonly misidentified lines (See ICLAC register) | none |

### Animals and other organisms

**Policy information about studies involving animals** - **ARRIVE guidelines** recommended for reporting animal research

| Laboratory animals | 6-8 week old C57BL/6I wild-type (H-2b) , BALB/C (H-2d) and thymus-deficient BALB/C nude mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). Both male and female mice were used for the study. |
| Wild animals | the study did not involve any wild animal. |
| Field-collected samples | the study did not involve samples collected from the field. |
| Ethics oversight | All the animal experiments were carried out in the animal unit, Tianjin Medical University (Tianjin, China) according to procedures authorized and specifically approved by the institutional ethical committee (Permit Number: SYXX 2009-0001). |

Note that full information on the approval of the study protocol must also be provided in the manuscript.
Human research participants

Policy information about studies involving human research participants

Population characteristics
Blood and serum samples from healthy volunteers were purchased from Tianjin Blood center (Tianjin, China), which is a commercial source. Serum samples from cancer patients were purchased from biobank of Tianjin Medical University Cancer Institute and Hospital (Tianjin, China, with the approval of the hospital ethic committee and Tianjin science and technology commission (Permit number (2016)621).

Recruitment
Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these may impact results.

Ethics oversight
Approved by the hospital ethic committee and Tianjin science and technology commission (Permit number (2016)621).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots
Confirm that:
- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation
Samples were prepared as described in the methods section. Animals were culled according to procedures authorized and specifically approved by the institutional ethical committee (permit SYXX 2009-0001). The single cell suspensions were prepared from spleen and LN’s by mashing tissues through a 70 μm cell strainer. Human peripheral blood was obtained from healthy volunteers (provided by Tianjin Blood Center, Tianjin, China). Single cell suspensions from liver or tumor tissues were minced into small pieces with surgical scissors, were digested in collagenase type IV suspension (0.05 mg/ml, Worthington Biochem, Corp., NJ, US), treated with the 70 μm cell strainer, then the mixture was re-suspended with 40% percoll (Pharmacal, Sweden) to remove the supernatant and with the ACK lysis buffer to remove red blood cells. Live/Dead stains were used to exclude dead cells. Peripheral blood mononuclear cells were isolated with human lymphoprep solution (Axis-shield PoCAS, Oslo, Norway) per the manufacturer’s instruction. Single cell suspensions collected for further analysis by flow cytometry.

Instrument
All data were collected on BD LSRFortessa instrument (BD Biosciences).

Software
Data analysis was performed using Flowin version 7.6 (Tree Star, USA).

Cell population abundance
For all cell populations analysed, abundances are indicated in the figure plots.

Gating strategy
All gate strategies captured cells by FSC vs SSC area, single cells by FSC height versus area. The PI-negative cells were gated as live cells for further analysis. Gating strategies beyond this differed by experiment.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.